                               SEQUENCE LISTING

<110> DSM IP ASSETS, B.V.
      MIDORI USA INC.
 
<120> METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC 
      PATHWAYS AND METABOLITES

<130> 54877-711.601

<140> PCT/US2021/022118
<141> 2021-03-12

<150> 62/989,107
<151> 2020-03-13

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 1
cggtgctgga gaaagaaggt                                                   20


<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 2
gattttagcc gcgccgattt                                                   20


<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 3
tgagctttgc acgctgtttc                                                   20


<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 4
tggtacaact atcgcgtcgg                                                   20


<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 5
cagttgtgcg gcggttaaaa                                                   20


<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 6
tacctgaccg atgacgtcct                                                   20


<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 7
gtttgccgag actttgccag                                                   20


<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 8
gtccaggaac agcgtacaca                                                   20


